```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  NOV 21   CAS patent coverage to include exemplified prophetic
                   substances identified in English-, French-, German-,
                   and Japanese-language basic patents from 2004-present
 NEWS  3  NOV 26   MARPAT enhanced with FSORT command
 NEWS  4  NOV 26   CHEMSAFE now available on STN Easy
 NEWS  5  NOV 26   Two new SET commands increase convenience of STN
                   searching
 NEWS  6  DEC 01   ChemPort single article sales feature unavailable
 NEWS  7  DEC 12   GBFULL now offers single source for full-text
                   coverage of complete UK patent families
 NEWS  8  DEC 17   Fifty-one pharmaceutical ingredients added to PS
 NEWS  9  JAN 06   The retention policy for unread STNmail messages
                   will change in 2009 for STN-Columbus and STN-Tokyo
 NEWS 10  JAN 07   WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
                   Classification Data
 NEWS 11  FEB 02   Simultaneous left and right truncation (SLART) added
                   for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
 NEWS 12  FEB 02   GENBANK enhanced with SET PLURALS and SET SPELLING
 NEWS 13  FEB 06   Patent sequence location (PSL) data added to USGENE
 NEWS 14  FEB 10   COMPENDEX reloaded and enhanced
 NEWS 15  FEB 11   WTEXTILES reloaded and enhanced
 NEWS 16  FEB 19   New patent-examiner citations in 300,000 CA/CAplus
                   patent records provide insights into related prior
                   art
 NEWS 17  FEB 19   Increase the precision of your patent queries -- use
                   terms from the IPC Thesaurus, Version 2009.01
 NEWS 18  FEB 23   Several formats for image display and print options
                   discontinued in USPATFULL and USPAT2
 NEWS 19  FEB 23   MEDLINE now offers more precise author group fields
                   and 2009 MeSH terms
 NEWS 20  FEB 23   TOXCENTER updates mirror those of MEDLINE - more
                   precise author group fields and 2009 MeSH terms
 NEWS 21  FEB 23   Three million new patent records blast AEROSPACE into
                   STN patent clusters
 NEWS 22  FEB 25   USGENE enhanced with patent family and legal status
                   display data from INPADOCDB
 NEWS 23  MAR 06   INPADOCDB and INPAFAMDB enhanced with new display
                   formats
 NEWS 24  MAR 11   EPFULL backfile enhanced with additional full-text
                   applications and grants
 NEWS 25  MAR 11   ESBIOBASE reloaded and enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 22:22:24 ON 13 MAR 2009

=> file uspatall
```

```
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     1.54       1.54

FILE 'USPATFULL' ENTERED AT 22:26:23 ON 13 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 22:26:23 ON 13 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 22:26:23 ON 13 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s tamsulosin
L1        1288 TAMSULOSIN

=> s tamsulosin/clm
L2         226 TAMSULOSIN/CLM

=> s polymer?
L3     1224605 POLYMER?

=> s polymer?/clm
L4      432182 POLYMER?/CLM

=> s (calcium or potassium or sodium or magnesium)
L5     1287207 (CALCIUM OR POTASSIUM OR SODIUM OR MAGNESIUM)

=> s (calcium or potassium or sodium or magnesium)/clm
L6      305082 (CALCIUM OR POTASSIUM OR SODIUM OR MAGNESIUM)/CLM

=> s (multilayer or layer)
L7     2063906 (MULTILAYER OR LAYER)

=> s (multilayer or layer)/clm
L8      810896 (MULTILAYER OR LAYER)/CLM

=> s capsule?
L9      243183 CAPSULE?

=> s capsule?/clm
L10      27197 CAPSULE?/CLM

=> s l1 and l4
L11        242 L1 AND L4

=> s l1 and l3
L12        897 L1 AND L3

=> s l5 and l12
L13        888 L5 AND L12

=> s l7 and l13
L14        600 L7 AND L13

=> s l9 and l14
L15        493 L9 AND L14

=> s l2 and l4
L16         50 L2 AND L4

=> s l6 and l16
L17         33 L6 AND L16

=> s l8 and l17
L18          6 L8 AND L17

=> s l10 and l18
L19          2 L10 AND L18

=> d 1-2
```

L19 ANSWER 1 OF 2 USPATFULL on STN
Full Text
AN 2009:4272 USPATFULL
TI Controlled release tamsulosin hydrochloride formulation
IN Cheng, Xiu Xiu, Weston, FL, UNITED STATES
Cheng, Xiufang, Weston, FL, UNITED STATES
PA Watson Pharmaceuticals, Inc. (U.S. corporation)
PI US 20090004284 A1 20090101
AI US 2007-821990 A1 20070626 (11)
DT Utility
FS APPLICATION
LN.CNT 567
INCL INCLM: 424/497.000
INCLS: 424/490.000; 514/603.000
NCL NCLM: 424/497.000
NCLS: 424/490.000; 514/603.000
IC IPCI A61K0009-14 [I,A]; A61K0031-18 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 2 OF 2 USPATFULL on STN
Full Text
AN 2008:253184 USPATFULL
TI Advanced drug development and manufacturing
IN Birnbaum, Eva R., Los Alamos, NM, UNITED STATES
Koppisch, Andrew T., Flagstaff, AZ, UNITED STATES
Baldwin, Sharon M., Santa Fe, NM, UNITED STATES
Warner, Benjamin P., Los Alamos, NM, UNITED STATES
McCleskey, T. Mark, Los Alamos, NM, UNITED STATES
Stewart, Jeffrey Joseph, Los Alamos, NM, UNITED STATES
Berger, Jennifer A., Los Alamos, NM, UNITED STATES
Harris, Michael N., Los Alamos, NM, UNITED STATES
Burrell, Anthony K., Los Alamos, NM, UNITED STATES
PI US 20080220441 A1 20080911
AI US 2007-974156 A1 20071010 (11)
RLI Continuation-in-part of Ser. No. US 2001-859701, filed on 16 May 2001, PENDING Continuation-in-part of Ser. No. US 2002-206524, filed on 25 Jul 2002, ABANDONED Continuation-in-part of Ser. No. US 2003-621825, filed on 16 Jul 2003, Pat. No. US 6858148
PRAI US 2006-850594P 20061010 (60)
DT Utility
FS APPLICATION
LN.CNT 10199
INCL INCLM: 435/071.000
INCLS: 436/501.000; 436/172.000; 436/086.000; 378/045.000
NCL NCLM: 435/007.100
NCLS: 378/045.000; 436/086.000; 436/172.000; 436/501.000
IC IPCI G01N0033-53 [I,A]; G01N0021-76 [I,A]; G01N0033-68 [I,A]; G01N0023-223 [I,A]; G01N0023-22 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l18 1-6

L18 ANSWER 1 OF 6 USPATFULL on STN
Full Text
AN 2009:4272 USPATFULL
TI Controlled release tamsulosin hydrochloride formulation
IN Cheng, Xiu Xiu, Weston, FL, UNITED STATES
Cheng, Xiufang, Weston, FL, UNITED STATES
PA Watson Pharmaceuticals, Inc. (U.S. corporation)
PI US 20090004284 A1 20090101
AI US 2007-821990 A1 20070626 (11)
DT Utility
FS APPLICATION
LN.CNT 567
INCL INCLM: 424/497.000
INCLS: 424/490.000; 514/603.000
NCL NCLM: 424/497.000
NCLS: 424/490.000; 514/603.000
IC IPCI A61K0009-14 [I,A]; A61K0031-18 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 2 OF 6 USPATFULL on STN
Full Text
AN 2008:354338 USPATFULL
TI Solid form
IN Darmuzey, Olivia, Brussels, BELGIUM
MacLeod, Graeme, Wezembeek Oppem, BELGIUM
Cengic, Dzenana, Brussels, BELGIUM
PI US 20080311162 A1 20081218
AI US 2007-803825 A1 20070516 (11)
DT Utility
FS APPLICATION
LN.CNT 1512
INCL INCLM: 424/401.000
INCLS: 424/490.000; 514/263.340
NCL NCLM: 424/401.000
NCLS: 424/490.000; 514/263.340
IC IPCI A61K0008-02 [I,A]; A61K0009-14 [I,A]; A61K0031-522 [I,A];
A61K0031-519 [I,C*]; C11D0017-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 3 OF 6 USPATFULL on STN
Full Text
AN 2008:268489 USPATFULL
TI UROLOGICAL MEDICAL DEVICES FOR RELEASE OF THERAPEUTIC AGENTS
IN Cheng, Eric, Bloomington, IN, UNITED STATES
Li, Jianmin, Lexington, MA, UNITED STATES
Bucay-Couto, Weena, Burlington, MA, UNITED STATES
Sanders, Scott, Hinsdale, IL, UNITED STATES
Schuermann, James F., Natick, MA, UNITED STATES
Sheu, Min-Shyan, Chelmsford, MA, UNITED STATES
PA Boston Scientific Scimed, Inc., Maple Grove, MN, UNITED STATES (U.S.
corporation)
PI US 20080234659 A1 20080925
AI US 2008-52037 A1 20080320 (12)
PRAI US 2007-919081P 20070320 (60)
DT Utility
FS APPLICATION
LN.CNT 1180
INCL INCLM: 604/523.000
INCLS: 623/023.660
NCL NCLM: 604/523.000
NCLS: 623/023.660
IC IPCI A61M0025-00 [I,A]; A61F0002-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 6 USPATFULL on STN
Full Text
AN 2008:253184 USPATFULL
TI Advanced drug development and manufacturing
IN Birnbaum, Eva R., Los Alamos, NM, UNITED STATES
Koppisch, Andrew T., Flagstaff, AZ, UNITED STATES
Baldwin, Sharon M., Santa Fe, NM, UNITED STATES
Warner, Benjamin P., Los Alamos, NM, UNITED STATES
McCleskey, T. Mark, Los Alamos, NM, UNITED STATES
Stewart, Jeffrey Joseph, Los Alamos, NM, UNITED STATES
Berger, Jennifer A., Los Alamos, NM, UNITED STATES
Harris, Michael N., Los Alamos, NM, UNITED STATES
Burrell, Anthony K., Los Alamos, NM, UNITED STATES
PI US 20080220441 A1 20080911
AI US 2007-974156 A1 20071010 (11)
RLI Continuation-in-part of Ser. No. US 2001-859701, filed on 16 May 2001,
PENDING Continuation-in-part of Ser. No. US 2002-206524, filed on 25 Jul
2002, ABANDONED Continuation-in-part of Ser. No. US 2003-621825, filed
on 16 Jul 2003, Pat. No. US 6858148
PRAI US 2006-850594P 20061010 (60)
DT Utility
FS APPLICATION
LN.CNT 10199
INCL INCLM: 435/071.000
INCLS: 436/501.000; 436/172.000; 436/086.000; 378/045.000
NCL NCLM: 435/007.100
NCLS: 378/045.000; 436/086.000; 436/172.000; 436/501.000

```
IC     IPCI   G01N0033-53 [I,A]; G01N0021-76 [I,A]; G01N0033-68 [I,A];
              G01N0023-223 [I,A]; G01N0023-22 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18  ANSWER 5 OF 6  USPATFULL on STN
Full Text
AN     2008:86578  USPATFULL
TI     Tamsulosin controlled-release tablet
IN     Gan, Yong, Huairou, CHINA
       Zhou, Xinteng, Huairou, CHINA
PA     Ocean Star International, Inc., Snowville, UT, UNITED STATES (non-U.S.
       corporation)
PI     US 20080075775      A1  20080327
AI     US 2006-580215      A1  20061011 (11)
PRAI   CN 2006-10153091    20060922
DT     Utility
FS     APPLICATION
LN.CNT 720
INCL   INCLM: 424/473.000
NCL    NCLM:  424/473.000
IC     IPCI   A61K0009-24 [I,A]
       IPCR   A61K0009-24 [I,C]; A61K0009-24 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18  ANSWER 6 OF 6  USPATFULL on STN
Full Text
AN     2007:140489  USPATFULL
TI     Sustained release formulations
IN     Cho, Seong Hwan, Suwon-city, KOREA, REPUBLIC OF
       Ku, Jeong, Yongin-city, KOREA, REPUBLIC OF
       Lim, Dong Kwon, Yongin-city, KOREA, REPUBLIC OF
       Cheon, Jun Hee, Suwon-city, KOREA, REPUBLIC OF
       An, Tae Kun, Yongin-city, KOREA, REPUBLIC OF
       Ko, Jae Kyoung, Incheon-city, KOREA, REPUBLIC OF
       Youn, Yong Sik, Yongin-city, KOREA, REPUBLIC OF
       Park, Choong Sil, Icheon-city, KOREA, REPUBLIC OF
       Suh, Hea Ran, Icheon-city, KOREA, REPUBLIC OF
       Yang, Eun Young, Suwon-city, KOREA, REPUBLIC OF
       Jeon, Eun Kyung, Yongin-city, KOREA, REPUBLIC OF
       Kim, Chang Ju, Suwon-city, KOREA, REPUBLIC OF
PA     CJ CORPORATION, Seoul, KOREA, REPUBLIC OF, 100-749 (non-U.S.
       corporation)
PI     US 20070122480      A1  20070531
AI     US 2004-574337      A1  20040925 (10)
       WO 2004-KR2496          20040925
                               20060509  PCT 371 date
PRAI   KR 2003-67588       20030929
       KR 2004-77158       20040924
DT     Utility
FS     APPLICATION
LN.CNT 799
INCL   INCLM: 424/472.000
NCL    NCLM:  424/472.000
IC     IPCI   A61K0009-24 [I,A]
       IPCR   A61K0009-24 [I,C]; A61K0009-24 [I,A]; A61K0009-22 [I,C*];
              A61K0009-22 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 22:22:24 ON 13 MAR 2009)

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 22:26:23 ON 13 MAR 2009
L1          1288 S TAMSULOSIN
L2           226 S TAMSULOSIN/CLM
L3       1224605 S POLYMER?
L4        432182 S POLYMER?/CLM
L5       1287207 S (CALCIUM OR POTASSIUM OR SODIUM OR MAGNESIUM)
L6        305082 S (CALCIUM OR POTASSIUM OR SODIUM OR MAGNESIUM)/CLM
L7       2063906 S (MULTILAYER OR LAYER)
L8        810896 S (MULTILAYER OR LAYER)/CLM
```

```
L9       243183 S CAPSULE?
L10       27197 S CAPSULE?/CLM
L11         242 S L1 AND L4
L12         897 S L1 AND L3
L13         888 S L5 AND L12
L14         600 S L7 AND L13
L15         493 S L9 AND L14
L16          50 S L2 AND L4
L17          33 S L6 AND L16
L18           6 S L8 AND L17
L19           2 S L10 AND L18

=> d l15 483-493

L15  ANSWER 483 OF 493  USPAT2 on STN
Full Text
AN      2003:100119  USPAT2
TI      Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
IN      Becker, Cyrus Kephra, Menlo Park, CA, UNITED STATES
        Caroon, Joan Marie, Mountain View, CA, UNITED STATES
        Melville, Chris Richard, Palo Alto, CA, UNITED STATES
        Padilla, Fernando, Fremont, CA, UNITED STATES
        Pfister, Jurg Roland, Los Altos, CA, UNITED STATES
        Zhang, Xiaoming, Campbell, CA, UNITED STATES
PA      Syntex (U.S.A.) LLC, Palo Alto, CA, UNITED STATES (U.S. corporation)
PI      US 6900220           B2  20050531
AI      US 2002-40319            20020102 (10)
PRAI    US 2001-259337P      20010102 (60)
        US 2001-325267P      20010927 (60)
DT      Utility
FS      GRANTED
LN.CNT 2798
INCL    INCLM: 514/266.210
        INCLS: 514/234.200; 514/234.500; 514/249.000; 514/252.170; 514/264.100;
               514/266.200; 544/116.000; 544/117.000; 544/279.000; 544/284.000;
               544/350.000
NCL     NCLM:  514/266.210; 514/223.200
        NCLS:  514/234.200; 514/234.500; 514/249.000; 514/252.170; 514/264.100;
               514/266.200; 544/116.000; 544/117.000; 544/279.000; 544/284.000;
               544/350.000; 544/012.000
IC      [7]
        ICM    A61K031-517
        ICS    A61K031-535; C07D487-00; C07D417-00; C07D471-00
        IPCI   C07D0285-22 [ICM,7]; C07D0285-00 [ICM,7,C*]; A61K0031-549
               [ICS,7]; A61K0031-517 [ICS,7]
        IPCI-2 A61K0031-517 [ICM,7]; A61K0031-535 [ICS,7]; C07D0487-00 [ICS,7];
               C07D0417-00 [ICS,7]; C07D0471-00 [ICS,7]
        IPCR   A61K0031-517 [I,C*]; A61K0031-517 [I,A]; A61K0031-519 [I,C*];
               A61K0031-519 [I,A]; A61K0031-549 [I,C*]; A61K0031-549 [I,A];
               C07D0401-00 [I,C*]; C07D0401-04 [I,A]; C07D0401-14 [I,A];
               C07D0403-00 [I,C*]; C07D0403-14 [I,A]; C07D0405-00 [I,C*];
               C07D0405-14 [I,A]; C07D0417-00 [I,C*]; C07D0417-04 [I,A];
               C07D0417-14 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A];
               C07D0471-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
               C07D0491-00 [I,C*]; C07D0491-04 [I,A]
EXF     514/234.2; 514/234.5; 514/249; 514/252.17; 514/264.1; 514/266.2;
        514/266.21; 544/116; 544/117; 544/279; 544/284; 544/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15  ANSWER 484 OF 493  USPAT2 on STN
Full Text
AN      2003:92739  USPAT2
TI      Solid carriers for improved delivery of hydrophobic active ingredients
        in pharmaceutical compositions
IN      Patel, Mahesh V., Salt Lake City, UT, United States
        Chen, Feng-Jing, Salt Lake City, UT, United States
PA      Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)
PI      US 6569463           B2  20030527
AI      US 2001-800593           20010306 (9)
RLI     Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, now patented,
        Pat. No. US 6248363
DT      Utility
```

FS GRANTED
LN.CNT 3198
INCL INCLM: 424/497.000
INCLS: 424/422.000; 424/427.000; 424/430.000; 424/433.000; 424/434.000; 424/435.000; 424/436.000; 424/441.000; 424/451.000; 424/457.000; 424/463.000; 424/464.000; 424/465.000; 424/466.000; 424/470.000; 424/474.000; 424/476.000; 424/482.000; 424/490.000; 424/489.000; 424/498.000; 514/773.000; 514/784.000; 514/785.000; 514/786.000; 514/779.000
NCL NCLM: 424/497.000; 424/465.000
NCLS: 424/422.000; 424/427.000; 424/430.000; 424/433.000; 424/434.000; 424/435.000; 424/436.000; 424/441.000; 424/451.000; 424/457.000; 424/463.000; 424/464.000; 424/465.000; 424/466.000; 424/470.000; 424/474.000; 424/476.000; 424/482.000; 424/489.000; 424/490.000; 424/498.000; 514/773.000; 514/779.000; 514/784.000; 514/785.000; 514/786.000; 977/906.000; 977/927.000
IC [7]
ICM A61K009-16
ICS A61K009-28; A61K009-32; A61K009-52; A61K009-56; A61K009-58
IPCI A61K0009-20 [ICM,7]; A61K0009-16 [ICS,7]; A61K0009-50 [ICS,7]
IPCI-2 A61K0009-16 [ICM,7]; A61K0009-28 [ICS,7]; A61K0009-32 [ICS,7]; A61K0009-30 [ICS,7,C*]; A61K0009-52 [ICS,7]; A61K0009-56 [ICS,7]; A61K0009-58 [ICS,7]; A61K0009-52 [ICS,7,C*]
IPCR A61K0009-02 [I,C*]; A61K0009-02 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A]; A61K0009-16 [I,C*]; A61K0009-16 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-30 [I,C*]; A61K0009-32 [I,A]; A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-51 [I,C*]; A61K0009-51 [I,A]; A61K0009-52 [I,C*]; A61K0009-52 [I,A]; A61K0009-54 [I,A]; A61K0009-56 [I,A]; A61K0009-58 [I,A]; A61K0031-21 [I,C*]; A61K0031-216 [I,A]; A61K0031-232 [I,A]; A61K0031-351 [I,C*]; A61K0031-351 [I,A]; A61K0031-366 [I,C*]; A61K0031-366 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A]; A61K0031-403 [I,C*]; A61K0031-404 [I,A]; A61K0031-415 [I,C*]; A61K0031-415 [I,A]; A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-421 [I,C*]; A61K0031-421 [I,A]; A61K0031-4353 [I,C*]; A61K0031-436 [I,A]; A61K0031-4409 [I,C*]; A61K0031-4409 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-472 [I,C*]; A61K0031-4725 [I,A]; A61K0031-519 [I,C*]; A61K0031-522 [I,A]; A61K0031-57 [I,C*]; A61K0031-57 [I,A]; A61K0031-64 [I,C*]; A61K0031-64 [I,A]; A61K0031-662 [I,C*]; A61K0031-663 [I,A]; A61K0038-23 [I,C*]; A61K0038-23 [I,A]; A61K0047-02 [I,C*]; A61K0047-02 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-22 [I,C*]; A61K0047-22 [I,A]; A61K0047-26 [I,C*]; A61K0047-26 [I,A]; A61K0047-28 [I,C*]; A61K0047-28 [I,A]; A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]; A61K0047-38 [I,C*]; A61K0047-38 [I,A]; A61K0047-44 [I,C*]; A61K0047-44 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0003-00 [I,C*]; A61P0003-04 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A]; A61P0005-00 [I,C*]; A61P0005-16 [I,A]; A61P0005-24 [I,A]; A61P0005-40 [I,A]; A61P0007-00 [I,C*]; A61P0007-02 [I,A]; A61P0007-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-04 [I,A]; A61P0009-06 [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A]; A61P0013-00 [I,C*]; A61P0013-08 [I,A]; A61P0015-00 [I,C*]; A61P0015-10 [I,A]; A61P0017-00 [I,C*]; A61P0017-12 [I,A]; A61P0019-00 [I,C*]; A61P0019-06 [I,A]; A61P0019-10 [I,A]; A61P0021-00 [I,C*]; A61P0021-02 [I,A]; A61P0025-00 [I,C*]; A61P0025-04 [I,A]; A61P0025-06 [I,A]; A61P0025-08 [I,A]; A61P0025-16 [I,A]; A61P0025-20 [I,A]; A61P0025-22 [I,A]; A61P0025-26 [I,A]; A61P0025-28 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0033-00 [I,C*]; A61P0033-06 [I,A]; A61P0033-10 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
EXF 424/422; 424/433; 424/436; 424/435; 424/440; 424/451; 424/452; 424/464; 424/465; 424/482; 424/489; 424/490; 424/480; 424/463; 424/470; 424/497; 424/498; 424/476; 424/427; 424/430; 424/434; 424/441; 424/466; 424/474
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 485 OF 493 USPAT2 on STN

Full Text
AN 2003:78121 USPAT2
TI Modified release formulations containing a hypnotic agent
IN Lemmens, Jacobus M., Mook, NETHERLANDS
van den Heuvel, Dennie J. M., Boxmeer, NETHERLANDS
Platteeuw, Johannes J., s'Hertogenbosch, NETHERLANDS
van Dalen, Frans, Nijmegen, NETHERLANDS
PA Synthon BV, Nijmegen, NETHERLANDS (non-U.S. corporation)
PI US 6638535 B2 20031028
AI US 2001-833662 20010413 (9)
PRAI US 2000-196939P 20000413 (60)
DT Utility
FS GRANTED
LN.CNT 902
INCL INCLM: 424/489.000
INCLS: 424/490.000; 424/464.000; 424/465.000; 514/300.000; 514/781.000
NCL NCLM: 424/489.000
NCLS: 424/464.000; 424/465.000; 424/490.000; 514/300.000; 514/781.000
IC [7]
ICM A61K009-20
ICS A61K009-14; A61K009-16; A61K031-44; A61K047-00
IPCI A61K0009-14 [ICM,7]
IPCI-2 A61K0009-20 [ICM,7]; A61K0009-14 [ICS,7]; A61K0009-16 [ICS,7]; A61K0031-44 [ICS,7]; A61K0047-00 [ICS,7]
IPCR A61K0009-16 [I,C*]; A61K0009-16 [I,A]; A61K0009-26 [I,C*]; A61K0009-26 [I,A]; A61K0031-4353 [I,C*]; A61K0031-437 [I,A]; A61K0031-519 [I,C*]; A61K0031-519 [I,A]
EXF 424/489; 424/490; 424/464; 424/465; 514/300; 514/781
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 486 OF 493 USPAT2 on STN
Full Text
AN 2002:308400 USPAT2
TI Heterocyclic compounds their production and use
IN Tasaka, Akihiro, Suita, JAPAN
Hitaka, Takenori, Takarazuka, JAPAN
Matsutani, Etsuya, Suita, JAPAN
PA Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)
PI US 6716863 B2 20040406
WO 2001077107 20011018
AI US 2001-889974 20010724 (9)
WO 2001-JP2937 20010405
PRAI JP 2000-106836 20000407
DT Utility
FS GRANTED
LN.CNT 3144
INCL INCLM: 514/374.000
INCLS: 548/235.000
NCL NCLM: 514/374.000
NCLS: 548/235.000
IC [7]
ICM A61K031-422
ICS C07D413-12
IPCI C07D0413-02 [ICM,7]; C07D0413-00 [ICM,7,C*]; A61K0031-422 [ICS,7]
IPCI-2 A61K0031-422 [ICM,7]; C07D0413-12 [ICS,7]; C07D0413-00 [ICS,7,C*]
IPCR A61P0035-00 [I,C*]; A61P0035-00 [I,A]; C07D0263-00 [I,C*]; C07D0263-32 [I,A]; C07D0413-00 [I,C*]; C07D0413-12 [I,A]
EXF 514/374; 548/235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 487 OF 493 USPAT2 on STN
Full Text
AN 2002:301622 USPAT2
TI Benzimidazoles that are useful in treating male sexual dysfunction
IN Cowart, Marlon D., Round Lake Beach, IL, UNITED STATES
Bhatia, Pramila A., Libertyville, IL, UNITED STATES
Daanen, Jerome F., Racine, WI, UNITED STATES
Stewart, Andrew O., Libertyville, IL, UNITED STATES
Patel, Meena V., Green Oaks, IL, UNITED STATES
Kolasa, Teodozyj, Lake Villa, IL, UNITED STATES
Brioni, Jorge D., Vernon Hills, IL, UNITED STATES
Rohde, Jeffrey, Evanston, IL, UNITED STATES

PA Abbott Laboratories, Abbott Park, IL, UNITED STATES (U.S. corporation)
PI US 7022728 B2 20060404
AI US 2002-94265 20020308 (10)
PRAI US 2001-340452P 20011214 (60)
US 2001-296078P 20010605 (60)
US 2001-274805P 20010309 (60)
DT Utility
FS GRANTED
LN.CNT 2990
INCL INCLM: 514/395.000
INCLS: 514/394.000; 514/393.000; 514/252.140; 514/254.060; 514/253.010
NCL NCLM: 514/395.000; 514/252.190
NCLS: 514/252.140; 514/253.010; 514/254.060; 514/393.000; 514/394.000; 514/253.090; 514/254.030
IC IPCI A61K0031-496 [ICM,7]
IPCI-2 A61K0031-415 [I,A]; A61K0031-495 [I,A]; A61K0031-50 [I,A]
IPCR A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-415 [I,A]; A61K0031-415 [I,C]; A61K0031-495 [I,C]; A61K0031-495 [I,A]; A61K0031-50 [I,C]; A61K0031-50 [I,A]
EXF 514/255; 514/258; 514/394; 514/393; 514/359; 514/362; 514/363; 514/385; 514/395; 514/252.14; 514/254.06; 514/253.01
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 488 OF 493 USPAT2 on STN
Full Text
AN 2002:288146 USPAT2
TI As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation
IN Tam, Peter, Redwood City, CA, UNITED STATES
Gesundheit, Neil, Los Altos, CA, UNITED STATES
Wilson, Leland F., Menlo Park, CA, UNITED STATES
PA Vivus, Inc., Mountain View, CA, UNITED STATES (U.S. corporation)
PI US 6946141 B2 20050920
AI US 2001-996407 20011121 (9)
RLI Continuation-in-part of Ser. No. US 2000-721412, filed on 21 Nov 2000, Pat. No. US 6495154
DT Utility
FS GRANTED
LN.CNT 1495
INCL INCLM: 424/423.000
INCLS: 424/434.000; 424/435.000; 424/443.000; 424/449.000; 424/451.000; 424/464.000; 424/045.000; 424/046.000
NCL NCLM: 424/423.000; 514/278.000
NCLS: 424/045.000; 424/046.000; 424/434.000; 424/435.000; 424/443.000; 424/449.000; 424/451.000; 424/464.000
IC [7]
ICM A61F002-02
ICS A61F013-02; A61K009-48; A61K009-70; A61K009-04
IPCI A61K0031-44 [ICM,7]
IPCI-2 A61F0002-02 [ICM,7]; A61F0013-02 [ICS,7]; A61K0009-48 [ICS,7]; A61K0009-70 [ICS,7]; A61K0009-04 [ICS,7]
IPCR A61K0009-02 [I,C*]; A61K0009-02 [I,A]; A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-12 [I,C*]; A61K0009-12 [I,A]; A61K0009-19 [I,C*]; A61K0009-19 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-46 [I,C*]; A61K0009-46 [I,A]; A61K0031-135 [I,C*]; A61K0031-135 [I,A]; A61K0031-136 [I,C*]; A61K0031-136 [I,A]; A61K0031-403 [I,C*]; A61K0031-404 [I,A]; A61K0031-55 [I,C*]; A61K0031-55 [I,A]; A61K0031-551 [I,C*]; A61K0031-551 [I,A]; A61K0031-553 [I,C*]; A61K0031-553 [I,A]; A61K0031-554 [I,C*]; A61K0031-554 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0045-06 [I,A]; A61K0047-34 [I,C*]; A61K0047-34 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
EXF 424/423; 424/434; 424/435; 424/443; 424/449; 424/451; 424/464; 424/45; 424/46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 489 OF 493 USPAT2 on STN
Full Text
AN 2002:67175 USPAT2
TI Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation

IN Wilson, Leland F., Menlo Park, CA, United States
Doherty, Jr., Paul C., Cupertino, CA, United States
Place, Virgil A., Kawaihae, HI, United States
Smith, William L., Montclair, NJ, United States
Abdel-Hamid Abdou Ali, Ibrahim AbouBakr, Mansoura, EGYPT
PA Vivus, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6403597 B2 20020611
AI US 2001-888250 20010621 (9)
RLI Continuation-in-part of Ser. No. US 1999-467094, filed on 10 Dec 1999
Continuation-in-part of Ser. No. US 1998-181070, filed on 27 Oct 1998, now patented, Pat. No. US 6037346, issued on 14 Mar 2000
Continuation-in-part of Ser. No. US 1997-958816, filed on 28 Oct 1997, now abandoned
DT Utility
FS GRANTED
LN.CNT 2030
INCL INCLM: 514/256.000
NCL NCLM: 514/256.000; 514/001.000
IC [7]
ICM A61K031-50
IPCI A61K0031-00 [ICM,7]
IPCI-2 A61K0031-50 [ICM,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-343 [I,C*]; A61K0031-343 [I,A]; A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A]; A61K0031-4015 [I,C*]; A61K0031-4015 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4164 [I,A]; A61K0031-4166 [I,A]; A61K0031-426 [I,C*]; A61K0031-426 [I,A]; A61K0031-4353 [I,C*]; A61K0031-437 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4704 [I,C*]; A61K0031-4704 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-50 [I,C*]; A61K0031-50 [I,A]; A61K0031-502 [I,C*]; A61K0031-502 [I,A]; A61K0031-5025 [I,C*]; A61K0031-5025 [I,A]; A61K0031-505 [I,C*]; A61K0031-505 [I,A]; A61K0031-519 [I,C*]; A61K0031-519 [I,A]; A61K0031-52 [I,A]; A61K0031-522 [I,A]; A61K0031-5375 [I,C*]; A61K0031-538 [I,A]; A61K0031-549 [I,C*]; A61K0031-549 [I,A]; A61K0031-551 [I,C*]; A61K0031-5513 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
EXF 514/258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 490 OF 493 USPAT2 on STN
Full Text
AN 2002:55008 USPAT2
TI Clear oil-containing pharmaceutical compositions containing a therapeutic agent
IN Chen, Feng-Jing, Salt Lake City, UT, United States
Patel, Mahesh V., Salt Lake City, UT, United States
Fikstad, David T., Salt Lake City, UT, United States
PA Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)
PI US 6761903 B2 20040713
AI US 2001-877541 20010608 (9)
RLI Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, now patented, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2000-751968, filed on 29 Dec 2000, now patented, Pat. No. US 6458383 Continuation-in-part of Ser. No. US 1999-375636, filed on 17 Aug 1999, now patented, Pat. No. US 6309663
DT Utility
FS GRANTED
LN.CNT 3614
INCL INCLM: 424/451.000
INCLS: 424/043.000; 424/433.000; 424/436.000; 424/441.000; 424/445.000; 424/455.000; 424/456.000; 424/458.000; 424/463.000; 424/464.000; 424/465.000; 424/489.000; 424/490.000; 424/725.000; 514/772.200; 514/772.300; 514/777.000; 514/779.000; 514/781.000; 514/783.000; 514/784.000; 514/785.000; 514/786.000; 514/937.000; 514/944.000
NCL NCLM: 424/451.000; 514/054.000
NCLS: 424/043.000; 424/433.000; 424/436.000; 424/441.000; 424/445.000; 424/455.000; 424/456.000; 424/458.000; 424/463.000; 424/464.000; 424/465.000; 424/489.000; 424/490.000; 424/725.000; 514/772.200; 514/772.300; 514/777.000; 514/779.000; 514/781.000; 514/783.000;

514/784.000; 514/785.000; 514/786.000; 514/937.000; 514/944.000;
424/727.000; 424/731.000; 424/750.000; 424/757.000
IC [7]
ICM A61K009-08
ICS A61K009-10; A61K009-14; A61K009-20; A61K009-48
IPCI A61K0031-715 [ICM,7]; A61K0035-78 [ICS,7]
IPCI-2 A61K0009-08 [ICM,7]; A61K0009-10 [ICS,7]; A61K0009-14 [ICS,7];
A61K0009-20 [ICS,7]; A61K0009-48 [ICS,7]
IPCR A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0036-185 [I,C*];
A61K0036-47 [I,A]
EXF 424/451; 424/450; 424/433; 424/436; 424/441; 424/443; 424/445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 491 OF 493 USPAT2 on STN
Full Text
AN 2002:27516 USPAT2
TI Compounds and methods to increase plasma HDL cholesterol levels and
improve HDL functionality
IN Luchoomun, Jayraz, Lilburn, GA, UNITED STATES
Meng, Charles Q., Alpharetta, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Sikorski, James A., Alpharetta, GA, UNITED STATES
PA Atherogenics, Inc., Alpharetta, GA, UNITED STATES (U.S. corporation)
PI US 6881860 B2 20050419
AI US 2001-833407 20010411 (9)
PRAI US 2000-196201P 20000411 (60)
DT Utility
FS GRANTED
LN.CNT 3107
INCL INCLM: 562/426.000
INCLS: 514/568.000
NCL NCLM: 562/426.000; 514/517.000
NCLS: 514/571.000; 514/649.000; 558/037.000; 564/347.000
IC [7]
ICM C07C321-00
IPCI A61K0031-255 [ICM,7]; A61K0031-21 [ICM,7,C*]; A61K0031-192
[ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0031-145 [ICS,7]
IPCI-2 C07C0321-00 [ICM,7]
IPCR C07C0323-00 [I,C*]; C07C0323-20 [I,A]; G01N0033-92 [I,C*];
G01N0033-92 [I,A]
EXF 562/426; 514/568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 492 OF 493 USPAT2 on STN
Full Text
AN 2002:21845 USPAT2
TI Compositions and methods for improved delivery of hydrophobic agents
IN Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
PA Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)
PI US 6451339 B2 20020917
AI US 2001-898553 20010702 (9)
RLI Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, now
patented, Pat. No. US 6294192
DT Utility
FS GRANTED
LN.CNT 2907
INCL INCLM: 424/451.000
INCLS: 424/450.000; 424/455.000; 424/456.000; 424/463.000; 424/489.000;
424/499.000; 424/502.000; 424/435.000; 424/464.000; 424/937.000;
424/938.000; 424/939.000; 514/940.000; 514/941.000; 514/942.000;
514/943.000; 514/975.000
NCL NCLM: 424/451.000; 424/400.000
NCLS: 424/435.000; 424/450.000; 424/455.000; 424/456.000; 424/463.000;
424/464.000; 424/489.000; 424/499.000; 424/502.000; 514/937.000;
514/938.000; 514/939.000; 514/940.000; 514/941.000; 514/942.000;
514/943.000; 514/975.000
IC [7]
ICM A61K009-127
IPCI A61K0009-00 [ICM,7]
IPCI-2 A61K0009-127 [ICM,7]
IPCR A61K0009-48 [I,C*]; A61K0009-48 [I,A]; A61K0031-57 [I,C*];

A61K0031-57 [I,A]; A61K0038-12 [I,C*]; A61K0038-13 [I,A]
EXF 424/450; 424/451; 424/455; 424/456; 424/463; 424/489; 424/499; 424/502; 424/435; 424/464; 514/937; 514/938; 514/939; 514/940; 514/941; 514/943; 514/975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 493 OF 493 USPAT2 on STN
Full Text
AN 2001:229703 USPAT2
TI Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction
IN Place, Virgil A., Kawaihae, HI, United States
Wilson, Leland F., Menlo Park, CA, United States
Doherty, Jr., Paul C., Cupertino, CA, United States
Hanamoto, Mark S., Belmont, CA, United States
Spivack, Alfred P., Menlo Park, CA, United States
Gesundheit, Neil, Los Altos, CA, United States
Bennett, Sean R., Denver, CO, United States
PA Vivus, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6593313 B2 20030715
AI US 2001-905458 20010713 (9)
RLI Continuation of Ser. No. US 2000-539484, filed on 30 Mar 2000, now patented, Pat. No. US 6306841 Continuation of Ser. No. US 1998-181316, filed on 27 Oct 1998, now abandoned Continuation-in-part of Ser. No. US 1997-959064, filed on 28 Oct 1997, now patented, Pat. No. US 5877216 Continuation-in-part of Ser. No. US 1997-959057, filed on 28 Oct 1997, now abandoned
DT Utility
FS GRANTED
LN.CNT 1331
INCL INCLM: 514/108.000
NCL NCLM: 514/108.000; 514/530.000
NCLS: 514/288.000; 514/573.000
IC [7]
ICM A61K031-19
ICS A61K031-557
IPCI A61K0031-5575 [ICM,7]; A61K0031-557 [ICM,7,C*]; A61K0031-48 [ICS,7]
IPCI-2 A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C*]; A61K0031-557 [ICS,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-02 [N,C*]; A61K0009-02 [N,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-15 [I,C*]; A61K0031-15 [I,A]; A61K0031-21 [I,C*]; A61K0031-21 [I,A]; A61K0031-28 [I,C*]; A61K0031-28 [I,A]; A61K0031-295 [I,A]; A61K0031-48 [I,C*]; A61K0031-48 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61K0031-557 [I,C*]; A61K0031-557 [I,A]; A61K0031-5575 [I,A]; A61K0031-5585 [I,A]; A61K0031-56 [I,C*]; A61K0031-56 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
EXF 514/573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l15 kwic 492

L15 ANSWER 492 OF 493 USPAT2 on STN
DETD The POE-POP block copolymers are a unique class of **polymeric** surfactants. The unique structure of the surfactants, with hydrophilic POE and hydrophobic POP moieties in well-defined ratios and positions, provides. . . Synperonic PE series (ICI); Pluronic® series (BASF), Emkalyx, Lutrol (BASF), Supronic, Monolan, Pluracare, and Plurodac. The generic term for these **polymers** is "poloxamer" (CAS 9003-11-6). These **polymers** have the formula:
DETD . . . use in the present invention. Preferred anionic surfactants include fatty acid salts and bile salts. Specifically, preferred ionic surfactants include **sodium** oleate, **sodium** lauryl sulfate, **sodium** lauryl sarcosinate, **sodium** dioctyl sulfosuccinate, **sodium** cholate, and **sodium** taurocholate. Examples of such surfactants are shown in Table 18 below. For simplicity, typical counterions are shown in the entries. . . in the art, however, that any bioacceptable counterion may be used. For example, although the fatty acids are shown as **sodium** salts, other cation counterions can also be used, such as alkali metal cations or ammonium. Unlike typical non-ionic surfactants, these. . .

DETD
TABLE 18

Ionic Surfactants
COMPOUND HLB

FATTY ACID SALTS >10
Sodium caproate
Sodium caprylate
Sodium caprate
Sodium laurate
Sodium myristate
Sodium myristolate
Sodium palmitate
Sodium palmitoleate
Sodium oleate 18
Sodium ricinoleate
Sodium linoleate
Sodium linolenate
Sodium stearate
Sodium lauryl sulfate (dodecyl) 40
Sodium tetradecyl sulfate
Sodium lauryl sarcosinate
Sodium dioctyl sulfosuccinate [**sodium** docusate (Cytec)]
BILE SALTS >10
Sodium cholate
Sodium taurocholate
Sodium glycocholate
Sodium deoxycholate
Sodium taurodeoxycholate
Sodium glycodeoxycholate
Sodium ursodeoxycholate
Sodium chenodeoxycholate
Sodium taurochenodeoxycholate
Sodium glyco cheno deoxycholate
Sodium cholylsarcosinate
Sodium N-methyl taurocholate
PHOSPHOLIPIDS
Egg/Soy lecithin [Epikuron .TM. (Lucas Meyer), Ovothin .TM. (Lucas Meyer)]
Lyso egg/soy lecithin
Hydroxylated lecithin
Lysophosphatidylcholine
Cardiolipin
Sphingomyelin
Phosphatidylcholine
Phosphatidyl ethanolamine
Phosphatidic acid
Phosphatidyl glycerol
Phosphatidyl serine
PHOSPHORIC ACID ESTERS
Diethanolammonium polyoxyethylene-10. . . fatty alcohol ethoxylates with phosphoric acid or anhydride
CARBOXYLATES
Ether carboxylates (by oxidation of terminal OH group of fatty alcohol ethoxylates)
Succinylated monoglycerides [LAMEGIN ZE (Henkel)]
Sodium stearyl fumarate
Stearoyl propylene glycol hydrogen succinate
Mono/diacetylated tartaric acid esters of mono- and diglycerides
Citric acid esters of mono-, diglycerides
Glyceryl-lacto esters of fatty acids (CFR ref. 172.852)
Acyl lactylates:
lactylic esters of fatty acids
calcium/**sodium** stearoyl-2-lactylate
calcium/**sodium** stearoyl lactylate
Alginate salts
Propylene glycol alginate
SULFATES AND SULFONATES
Ethoxylated alkyl sulfates
Alkyl benzene sulfones
α-olefin sulfonates

Acyl isethionates
Acyl taurates
Alkyl glyceryl ether sulfonates
Octyl sulfosuccinate disodium
Disodium undecylenamideo-MEA-sulfosuccinate
CATIONIC. . .
DETD A third method of determining optical clarity and carrier diffusivity through the aqueous boundary **layer** is to quantitatively measure the size of the particles of which the dispersion is composed. These measurements can be performed. . .
DETD analgesics and anti-inflammatory agents, such as aloxiprin, auranofin, azapropazone, benorylate, capsaicin, celecoxib, diclofenac, diflunisal, etodolac, fenbufen, fenoprofen **calcium**, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, leflunomide, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, refocoxib, sulindac, tetrahydrocannabinol, tramadol. . .
DETD anti-epileptics, such as beclamide, carbamazepine, clonazepam, ethotoin, felbamate, fosphenytoin **sodium**, lamotrigine, methoin, methsuximide, methylphenobarbitone, oxcarbazepine, paramethadione, phenacemide, phenobarbitone, phenytoin, phensuximide, primidone, sulthiame, tiagabine HCl, topiramate, valproic acid, and vigabatrin;
DETD gastrointestinal agents, such as bisacodyl, cimetidine, cisapride, diphenoxylate HCl, domperidone, famotidine, lansoprazole, loperamide, mesalazine, nizatidine, omeprazole, ondansetron HCl, rabeprazole **sodium**, ranitidine HCl and sulphasalazine;
DETD muscle relaxants, such as dantrolene **sodium** and tizanidine HCl;
DETD and others, such as becaplermin, donepezil HCl, L-thryroxine, methoxsalen, verteporfrin, physostigmine, pyridostigmine, raloxifene HCl, sibutramine HCl, sildenafil citrate, tacrine, **tamsulosin** HCl, and tolterodine.
DETD . . . a semi-solid dispersion or a solid dispersion. If desired, the compositions may be encapsulated in a hard or soft gelatin **capsule**, a starch **capsule** or an enteric coated **capsule**. The term "enteric coated **capsule**" as used herein means a **capsule** coated with a coating resistant to acid; i.e., an acid resistant enteric coating. Although solubilizers are typically used to enhance. . . of a hydrophobic therapeutic agent, they may also render the compositions more suitable for encapsulation in hard or soft gelatin **capsules**. Thus, the use of a solubilizer such as those described above is particularly preferred in **capsule** dosage forms of the pharmaceutical compositions. If present, these solubilizers should be added in amounts sufficient to impart to the. . .
DETD . . . is mono-modal and narrow. This reduced and more uniform size enables more efficient drug transport through the intestinal aqueous boundary **layer**, and through the absorptive brush border membrane. More efficient transport to absorptive sites leads to improved and more consistent absorption. . .
DETD . . . conditions which limit production of lipase, such as pancreatic lipase secretory diseases; and dependence of lipolysis on stomach pH, endogenous **calcium** concentration, and presence of co-lipase or other digestion enzymes. The lack of lipolysis dependence further provides transport which does not. . .
DETD . . . the pharmaceutical compositions of the present invention allow for faster transport of the hydrophobic therapeutic agent through the aqueous boundary **layer**.
DETD . . . the hydrophobic therapeutic agent. A third solution was prepared with simulated intestinal fluid, plus an additional aliquot of 20 mM **sodium** taurocholate (a bile salt); this solution is designated SIFB in Table 29. Finally, a fourth solution was prepared with simulated intestinal fluid, 20 mM **sodium** taurocholate, and 5 mM lecithin; this solution is designated SIFBL. The 20 mM bile salt and 5 mM lecithin concentrations. . .
DETD

Cyclosporine 0.140 g
Cremophor RH-40 0.41 g
Arlacel 186 0.29 g
Sodium taurocholate 0.26 g
Propylene glycol 0.46 g
CLM What is claimed is:
. . . lecithins; lysolecithin and hydrogenated lysolecithins;

lysophospholipids and derivatives thereof; phospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; **sodium** docusate; and mixtures thereof.

CLM What is claimed is:
. . . and salts, analogues, and derivatives thereof; lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; **sodium** docusate; acyl lactylates; monoacetylated tartaric acid esters of monoglycerides, monoacetylated tartaric acid esters of diglycerides, diacetylated tartaric acid esters of. . .

CLM What is claimed is:
77. A dosage form comprising a **capsule** filled with the pharmaceutical formulation of any one of claims 69, 70, 71 or 72.

CLM What is claimed is:
78. The dosage form of claim 77, wherein the **capsule** is a hard gelatin **capsule**, a soft gelatin **capsule**, a starch **capsule** or an enteric coated **capsule**.

CLM What is claimed is:
88. The formulation of claim 1, wherein the formulation is contained in a **capsule**.

CLM What is claimed is:
95. The formulation of claim 89, wherein the formulation is contained in a **capsule**.

CLM What is claimed is:
105. The formulation of claim 104, wherein the formulation is contained in a **capsule**.

CLM What is claimed is:
107. The formulation of claim 106, wherein the formulation is contained in a **capsule**.

CLM What is claimed is:
117. The formulation of claim 116, wherein the formulation is contained in a **capsule**.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	42.32	43.86

STN INTERNATIONAL LOGOFF AT 22:34:21 ON 13 MAR 2009